BRISTOL-MYERS SQUIBB COMPANY Unrealized Gain (Loss) on Securities
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Unrealized Gain (Loss) on Securities of -$244.00 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-10-25.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnSecurities · last filed 2018-10-25
- BRISTOL-MYERS SQUIBB COMPANY unrealized gain (loss) on securities for the quarter ending 2018-09-30 was $97.00M, a 1840.00% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY unrealized gain (loss) on securities for the quarter ending 2017-09-30 was $5.00M.
| Period end | Unrealized Gain (Loss) on Securities 3 month | Unrealized Gain (Loss) on Securities 6 month | Unrealized Gain (Loss) on Securities 9 month |
|---|---|---|---|
| 2018-09-30 | $97.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | -$244.00M 10-Q · filed 2018-10-25 | |
| 2018-06-30 | -$341.00M 10-Q · filed 2018-07-26 | ||
| 2017-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | $17.00M 10-Q · filed 2018-10-25 | |
| 2017-06-30 | $12.00M 10-Q · filed 2018-07-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |